BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32392664)

  • 1. A cohort study on the association of MDM2 SNP309 with lung cancer risk in Bangladeshi population.
    Reza HA; Anamika WJ; Chowdhury MMK; Mostafa MG; Uddin MA
    Korean J Intern Med; 2020 May; 35(3):672-681. PubMed ID: 32392664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis.
    Bai J; Dai J; Yu H; Shen H; Chen F
    J Toxicol Environ Health A; 2009; 72(11-12):677-82. PubMed ID: 19492228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
    Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
    BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
    Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
    Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 SNP309 rs2279744 polymorphism and gastric cancer risk: a meta-analysis.
    Ma Y; Bian J; Cao H
    PLoS One; 2013; 8(2):e56918. PubMed ID: 23451111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene.
    Mittelstrass K; Sauter W; Rosenberger A; Illig T; Timofeeva M; Klopp N; Dienemann H; Meese E; Sybrecht G; Woelke G; Cebulla M; Degen M; Morr H; Drings P; Groeschel A; Kreymborg KG; Haeussinger K; Hoeffken G; Schmidt C; Jilge B; Schmidt W; Ko YD; Taeuscher D; Chang-Claude J; Wichmann HE; Bickeboeller H; Risch A
    BMC Cancer; 2008 Apr; 8():113. PubMed ID: 18433484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer.
    Leu JD; Wang CY; Tsai HY; Lin IF; Chen RC; Lee YJ
    Oncol Rep; 2011 Jun; 25(6):1755-63. PubMed ID: 21479369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.
    Qin X; Peng Q; Tang W; Lao X; Chen Z; Lai H; Deng Y; Mo C; Sui J; Wu J; Zhai L; Yang S; Li S; Zhao J
    PLoS One; 2013; 8(9):e76031. PubMed ID: 24098760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
    Zhao E; Cui D; Yuan L; Lu W
    Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer.
    Yoneda T; Kuboyama A; Kato K; Ohgami T; Okamoto K; Saito T; Wake N
    Oncol Rep; 2013 Jul; 30(1):25-34. PubMed ID: 23624782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.
    Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
    J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
    Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
    Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.
    Hamid S; Yang YH; Peng KN; Ismail SM; Zain RB; Lim KP; Wan Mustafa WM; Abraham MT; Teo SH; Cheong SC
    Oral Oncol; 2009 Jun; 45(6):496-500. PubMed ID: 18804411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
    Wan Y; Wu W; Yin Z; Guan P; Zhou B
    BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.
    Li Y; Zhao H; Sun L; Huang L; Yang Q; Kong B
    Hum Cell; 2011 Jun; 24(2):57-64. PubMed ID: 21547352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53 Arg72Pro and MDM2 SNP309 polymorphisms cooperate to increase lung adenocarcinoma risk in Chinese female non-smokers: a case control study.
    Ren YW; Yin ZH; Wan Y; Guan P; Wu W; Li XL; Zhou BS
    Asian Pac J Cancer Prev; 2013; 14(9):5415-20. PubMed ID: 24175836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis.
    Economopoulos KP; Sergentanis TN
    Breast Cancer Res Treat; 2010 Feb; 120(1):211-6. PubMed ID: 19590949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.